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Abstract This work was undertaken to establish the forms of
the calpain inhibitor, calpastatin, expressed in the brain tissue.
Five cDNA clones were obtained and the corresponding amino
acid sequences were deduced. Three of these proteins contain an
N-terminal domain (domain L) and four inhibitory repeats
typical of the calpastatin molecule. The other two are truncated
forms, containing the domain L, free or associated with a single
inhibitory repeat. Other differences, due to exon skipping,
produce calpastatin forms with different susceptibility to
posttranslational modifications. The more represented mRNA
form corresponds to a calpastatin molecule containing the four
inhibitory domains. These results may be useful to understand the
involvement of calpain in the onset of acute and degenerative
disorders of the central nervous system.
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1. Introduction
All eukaryotic cells contain a calcium-dependent proteolytic
system, consisting of one or more proteinases, named cal-
pains. The two well studied calpain forms are heterodimeric
proteins, distinguishable on the basis of calcium requirement
and composed of di¡erent catalytic 80 kDa subunits and of
identical small 30 kDa subunits [1^6]. These proteinases are
regulated in the cell by the presence of an inhibitory protein,
calpastatin, also localized in the cytosolic compartment [7].
Calpastatin interacts with the catalytic 80 kDa calpain sub-
unit, preventing its conversion to the low calcium requiring
autoproteolysed form, and consequently inhibiting the expres-
sion of its catalytic activity [8]. Phosphorylation of calpastatin
has been proposed as a mechanism that changes the speci¢city
of the inhibitor in isolated cells and in skeletal muscle [2,9].
Moreover, Mohan and Nixon [10] reported that multiple low
molecular weight forms of calpastatin are present in bovine
brain, probably produced by proteolysis of a larger precursor.
The e⁄ciency and the levels of calpastatin play an important
role in preventing the so-called pathological function of cal-
pains, which is triggered by degradation of the inhibitor pro-
tein, mediated by calpain [11,12].
Full-length or partial cDNA clones encoding calpastatin
have been obtained previously from mRNAs of various mam-
malian tissues or cell lines [13^20]. In the N-terminal region of
the protein sequences, deduced from human and rat cDNAs
and corresponding to the domain L of unknown function, the
presence of one or more peptide deletions, depending on the
tissue analyzed, has been identi¢ed [14^16]. Human genomic
DNA for calpastatin has also been sequenced and evidence
has been obtained for the alternative splicing mechanisms
producing deletion of one or more exons in domain L of
rat and human calpastatin mRNAs [15]. The full-length rat
liver cDNA for calpastatin, cloned previously [16], encoded a
domain L carrying the deletion of three peptides, correspond-
ing to exons 3, 4 and 6 [15], followed by four repetitive re-
gions, each containing the inhibitory consensus sequence
TIPPxYR [21]. Two other partial cDNA clones, obtained
from rat ¢broblasts, were found to encode calpastatins in
which peptides corresponding to exon 3 or to exons 3 and
6, respectively, were deleted [14]. Considering these ¢ndings,
we searched for mRNAs encoding calpastatin in rat brain.
Since the intracellular level of calpastatin is directly correlated
with the activation of calpain [22] and the brain tissue seems
highly sensitive to calpain-induced intracellular damages [23^
25], new information on the expression of calpastatin in brain
is important to understand the ‘pathological function’ of cal-
pastatin in this tissue.
2. Materials and methods
2.1. RNA isolation and cDNA synthesis
Total RNA was isolated from Sprague-Dawley rat brains by ex-
traction with guanidinium thiocyanate [26] and cDNA was synthe-
sized using MMLV reverse transcriptase (Promega) as described
[27]. The primers for PCR were selected externally to the translated
sequence of rat liver cDNA for calpastatin (accession number
X56729). The sense primer was 5P-CTGGCACATCTCCCAGAAT-
GAG-3P (nucleotides 1^22); the antisense primer was 5P-
TCAAAAGTCACCATCCACCAGC-3P (complementary to nucleoti-
des 1867^1888). PCR was carried out using AmpliTaq DNA polymer-
ase (Perkin Elmer) and 30 cycles of ampli¢cation as previously de-
scribed [27]. An aliquot (2 Wl) of the reaction mixture was then used
for cloning with the pGEM-T Vector System (Promega) as speci¢ed
by the manufacturer.
2.2. DNA sequencing
Puri¢ed plasmid DNAs were sequenced with the dideoxy chain
termination method [28] from both directions, using a Sequenase
2.0 kit (United States Biochemical Corp.). The presence of potential
posttranslational modi¢cation sites was established on the deduced
amino acid sequences with the PROSITE program [29] while the
presence of good PEST sequences [30] was determined with the PEST-
FIND program.
2.3. RNase protection assays
The plasmids containing the original cDNAs named RNCAST23
and RNCAST110 were used to synthesize antisense RNA probes.
Subclones of RNCAST103, RNCAST104 and RNCAST107 clones
were generated by PCR and cloned with the pGEM-T Vector System;
the sense primer was the 1^22 oligonucleotide reported above, the
antisense primer was 5P-GTGTCTATCAGGTCATCCAAAGC-3P
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(complementary to nucleotides 267^289 of rat liver calpastatin
cDNA; accession number X56729). The subclones were sequenced
and then linearized with SacI (clones RNCAST23 and RNCAST110)
followed by transcription with T7 RNA polymerase or ApaI (sub-
clones RNCAST103, RNCAST104 and RNCAST107) followed by
transcription with SP6 RNA polymerase. Transcriptions were carried
out using a MAXIscript Kit (Ambion, Inc.) using 62.5 pmol of [K-
32P]UTP (800 Ci/mmol) and 40 pmol of cold UTP in a volume of 20
Wl. The hybridization mixtures (20 Wl) contained 2 fmol of labeled
speci¢c probe, increasing amounts of rat brain RNA (0^20 Wg) and
a constant amount of total RNA (20 Wg), obtained by addition of
Torulla yeast RNA. After incubation at 50‡C for 18 h, RNase diges-
tion was performed at 37‡C for 30 min with RPA II kit (Ambion,
Inc.) by addition of RNase A (1.25 units) and RNase T1 (50 units).
The reaction was stopped with the RNase inactivation/precipitation
mixture and the precipitates subjected to electrophoresis on a 5%
polyacrylamide/urea gel. After autoradiography the protected frag-
ments were cut from the gel and quanti¢ed as described [31].
3. Results
3.1. Isolation of rat brain calpastatin cDNAs
Rat brain mRNAs for calpastatin were identi¢ed by RT-
PCR using two primers, based on the sequence reported pre-
viously for the 5P and 3P untranslated regions of rat liver
calpastatin cDNA [16]. The ampli¢ed DNA fragments were
separated by agarose gel electrophoresis and, as shown in Fig.
1, three bands with sizes of approximately 1900, 600 and 300
bp were obtained. To exclude that these bands were artifacts
of the ampli¢cation procedure, the PCR products were
cloned, sequenced and, among 50 randomly selected clones,
all encoded calpastatin molecules with molecular masses cor-
responding to the sizes of the PCR products. Particularly, 22
clones showed a sequence (RNCAST107) of 1858 bp, 12
(RNCAST103) of 1927 bp, seven (RNCAST110) of 328 bp,
¢ve (RNCAST23) of 606 bp and four (RNCAST104) of 2041
bp. These sequences showed high homology with the rat liver
cDNA for calpastatin [16], as demonstrated by their align-
ment, in both the translated and the 3P untranslated regions
(data not shown).
3.2. Structural analysis of calpastatin protein forms deduced
from cDNA sequences
Starting from the ¢rst methionine codon of the ¢ve cDNA
clones, an open reading frame encoded putative proteins of
616, 593, 654, 176 and 83 amino acid residues, respectively.
The alignment of the sequences of these proteins, together
with that of rat liver calpastatin described previously, revealed
a high degree of similarity among all the primary structures
(Fig. 2). In contrast, relevant di¡erences were found in the N-
terminal region of these calpastatin forms. In particular, we
found that all the brain calpastatin forms contained a 13-
residue peptide (residues 8^20), corresponding to exon 4
[15], absent in the liver form. In clones RNCAST104 and
RNCAST110, a second peptide of 38 residues was also found
(residues 39^76), corresponding to exon 6. In addition, the
putative protein encoded by clone RNCAST110 was a trun-
cated form of calpastatin, composed of 83 amino acids and
corresponding to a domain L of the molecule, without any
inhibitory domain. Furthermore, the 176-residue protein, en-
coded by clone RNCAST23, contained a domain L, lacking
exon 6, associated with an almost complete inhibitory do-
main. The three calpastatins having four inhibitory domains
also contained a peptide of seven residues, localized in the
fourth inhibitory domain, showing a sequence di¡erent from
that described for rat liver calpastatin. This change was due to
a short frame shift of the cDNAs in which were deleted the
nucleotide corresponding to T1603 of rat liver cDNA se-
quence (accession number X56729) followed by the insertion
of nucleotide C (clone RNCAST103 and RNCAST107) or T
(clone RNCAST104) between C1624 and T1625 in the cDNA
of rat liver calpastatin (data not shown).
To evaluate the possible biochemical relevance of these
multiple calpastatin forms in brain tissue, we analyzed on
each protein molecule the presence of characteristic posttrans-
lational modi¢cation sites which could be involved in the
modulation of calpastatin function. All rat brain calpastatins,
as compared to the liver form, contain an additional PKC
target site (Ser16) which increases the potential susceptibility
of the protein to phosphorylation in the N-terminal region
(Fig. 3). Those calpastatin forms having also the peptide cor-
responding to exon 6 possess a further site for PKC phos-
phorylation (Ser69), together with a N-myristoylation site
(Gly50). Moreover, rat brain calpastatins encoded by
RNCAST103, RNCAST104 and RNCAST107 clones show
a PKC phosphorylation site at positions 546, 584 or 523 re-
spectively. The truncated forms are lacking in good PEST
sequences, proposed signals for protein degradation [30].
3.3. Levels of the mRNA forms for calpastatin in rat brain
The amount of the ¢ve calpastatin transcripts in rat brain
was measured by the RNase protection assay method. Fol-
lowing the procedure employed [31], hybridization of increas-
ing amounts of rat brain RNA samples with speci¢c probes
for each calpastatin mRNA yielded amounts of protected
fragments, the localization of which is indicated by brackets
in Fig. 3, correlated with the quantity of starting material.
The results, reported in Table 1, indicated that RNCAST107
was the most abundant form, with a level of mRNA three
times higher than that of RNCAST103. The levels of the
other three calpastatin mRNAs were at least one order of
magnitude lower than that of RNCAST107.
4. Discussion
Regulation of calpain is accomplished by the competitive
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Fig. 1. Detection of rat brain calpastatin-related transcripts. Total
rat brain RNA was reverse transcribed and subjected to PCR as de-
scribed in Section 2. After 30 cycles of ampli¢cation, 10 Wl of the
reaction mixture was subjected to electrophoresis on a 1% agarose
gel. Lane A, products of ampli¢cation visualized by ethidium bro-
mide staining; lane B, AmpliSize DNA size standard 50^2000 bp
ladder (Bio-Rad): from the top: 2.00, 1.50, 1.00, 0.70, 0.50, 0.40,
0.30, 0.20, 0.1 kb.
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inhibitor calpastatin able to control autoproteolysis, expres-
sion of catalytic activity as well as insertion of the enzyme into
the plasma membrane, the preferred site for the activation of
calpain [8,32]. The a⁄nity of calpastatin for the autolysed
calpain form is greater than that for the native enzyme [8],
indicating that the structural and conformational changes oc-
curring during autoproteolysis favor the formation of the en-
zyme-inhibitor complex. Regulation of calpain activity is fur-
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Fig. 2. Comparison of the deduced amino acid sequences of rat brain calpastatins with the rat liver calpastatin. The sequences were aligned us-
ing the CLUSTAL program. The di¡erences between the primary structures of rat liver calpastatin (accession number P27321) and rat brain
calpastatins are shown in bold characters. The exon structure has been assigned, based on human gene mapping [16].
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ther complicated by the presence in the same cell compart-
ment of two proteinase isozymes, showing di¡erent catalytic
and functional properties [2^4]. Hence, regulation of calpain
activity requires cellular mechanisms capable of modifying
calpastatin inhibitory e⁄ciency together with its enzyme selec-
tivity. In vitro and in vivo, posttranslational modi¢cations of
calpastatin are promoted by a phosphorylation-dephosphoryl-
ation process which modi¢es calpastatin e⁄ciency and specif-
icity [2,9]. In addition, the levels of calpastatin may be de-
creased by a calpain-mediated proteolysis [33,34], producing
cell conditions in which the proteinase is more susceptible to
activation. The presence of multiple forms of calpastatin
seems to be a crucial requirement for the regulation of the
Ca2-dependent proteolytic system in many cell types [15]. We
now report that the Ca2-dependent proteolytic system of rat
brain contains ¢ve transcripts for calpastatin which encode
proteins di¡ering in amino acid sequence and molecular
size. The rat brain calpastatins identi¢ed here are distinguish-
able from the reported rat liver form by the presence of pep-
tides, corresponding to exons 4 and 6, in domain L. More-
over, clone RNCAST107 is characterized by the absence of a
peptide corresponding to exon 8. Three of these protein
forms, containing four inhibitory repeats, di¡er from the rat
liver form also at the level of a seven-residue peptide present
in the C-terminal end (fourth inhibitory repeat). These di¡er-
ences in the primary structure modify the susceptibility to
posttranslational modi¢cations of each rat brain calpastatin
form. In particular, regions containing PKC phosphorylating
sites or good PEST sequences can modulate calpastatin e⁄-
ciency, speci¢city and digestibility. The presence of very di¡er-
ent amounts of the transcripts encoding calpastatin, here iden-
ti¢ed in rat brain, suggests that some calpastatins are
probably expressed only in speci¢c brain regions. The identi-
¢cation of multiple mRNAs for calpastatin in rat brain and
the availability of the corresponding cDNAs is particularly
useful to produce recombinant calpastatin forms and hence
to study their speci¢city, activity, binding site on calpain iso-
zymes and susceptibility to proteolytic degradation, together
with their in situ studies.
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